KURA insider buying and SEC filings, explained
Kura Oncology, Inc. · CIK 1422143
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- ZETA ACQUISITION CORP III
Insider activity in the last 12 months
Bought
$2.4M
Insiders who bought
1
Sold (not marked 10b5-1)
$902K
Planned sales (10b5-1)
$2.5M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 28, 2026 | Planned (10b5-1) | Teresa Brophy Bair (Chief Legal Officer) sold 8,442 shares at $10.50 ($89K), marked as a 10b5-1 plan trade. Holdings down 4% to 187,002 shares. | SEC filing Filed Sep 29, 2026 |
| Sep 28–29, 2026 | Planned (10b5-1) | Kathleen Ford (President / COO) sold 10,574 shares between Sep 28 and Sep 29 at about $10.59 ($112K), marked as a 10b5-1 plan trade. Holdings down 7% to 142,986 shares. | SEC filing Filed Sep 29, 2026 |
| Sep 29, 2026 | Planned (10b5-1) | Mollie Leoni (Chief Medical Officer) sold 28,802 shares at about $10.75 ($310K), marked as a 10b5-1 plan trade. Holdings down 17% to 141,095 shares. | SEC filing Filed Sep 29, 2026 |
| Sep 28, 2026 | Sale | Mollie Leoni (Chief Medical Officer) sold 12,448 shares at $10.50 ($131K). Holdings down 7% to 169,897 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 29, 2026 |
| Sep 28, 2026 | Sale | Thomas James Doyle (SVP, Finance & Accounting) sold 4,607 shares at $10.50 ($48K). Holdings down 3% to 142,428 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 29, 2026 |
| Sep 28–29, 2026 | Planned (10b5-1) | Brian T. Powl (Chief Commercial Officer) sold 23,430 shares between Sep 28 and Sep 29 at about $10.69 ($250K), marked as a 10b5-1 plan trade. Holdings down 15% to 136,819 shares. | SEC filing Filed Sep 29, 2026 |
| Sep 28, 2026 | Sale | Brian T. Powl (Chief Commercial Officer) sold 9,020 shares at $10.50 ($95K). Holdings down 5% to 160,249 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 29, 2026 |
| Aug 24, 2026 | Purchase (code P) | Troy Edward Wilson (CEO and Director) bought 100,000 shares indirectly (by trust) at about $12.39 ($1.2M), reported as a purchase (code P). Holdings by trust up 26% to 479,194 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 24, 2026 |
| Aug 21, 2026 | Planned (10b5-1) | Brian T. Powl (Chief Commercial Officer) sold 4,345 shares at about $11.89 ($52K), marked as a 10b5-1 plan trade. Holdings down 3% to 169,269 shares. | SEC filing Filed Aug 24, 2026 |
| Aug 19, 2026 | Planned (10b5-1) | Teresa Brophy Bair (Chief Legal Officer) sold 31,487 shares at about $12.63 ($398K), marked as a 10b5-1 plan trade. Holdings down 14% to 195,444 shares. | SEC filing Filed Aug 21, 2026 |
| Aug 17, 2026 | Purchase (code P) | Troy Edward Wilson (CEO and Director) bought 100,000 shares indirectly (by trust) at about $11.12 ($1.1M), reported as a purchase (code P). Holdings by trust up 36% to 379,194 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 17, 2026 |
| Jun 18, 2026 | Planned (10b5-1) | Mollie Leoni (Chief Medical Officer) sold 84,929 shares at about $9.82 ($834K), marked as a 10b5-1 plan trade. Holdings down 32% to 182,345 shares. | SEC filing Filed Jun 22, 2026 |
| May 21, 2026 | Planned (10b5-1) | Brian T. Powl (Chief Commercial Officer) sold 10,000 shares at $11.00 ($110K), marked as a 10b5-1 plan trade. Holdings down 5% to 173,614 shares. | SEC filing Filed May 22, 2026 |
| May 19, 2026 | Planned (10b5-1) | Kathleen Ford (President / COO) sold 2,257 shares at about $9.08 ($20K), marked as a 10b5-1 plan trade. Holdings down 1% to 153,560 shares. | SEC filing Filed May 20, 2026 |
| May 19, 2026 | Planned (10b5-1) | Brian T. Powl (Chief Commercial Officer) sold 339 shares at $9.21 ($3K), marked as a 10b5-1 plan trade. Holdings down <1% to 183,614 shares. | SEC filing Filed May 20, 2026 |
| May 18, 2026 | Planned (10b5-1) | Teresa Brophy Bair (Chief Legal Officer) sold 2,256 shares at about $9.38 ($21K), marked as a 10b5-1 plan trade. Holdings down 1% to 226,931 shares. | SEC filing Filed May 20, 2026 |
| Jan 27, 2026 | Sale | Francis Burrows (Chief Scientific Officer) sold 1,311 shares at $8.46 ($11K). Holdings down 4% to 32,424 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 27, 2026 |
| Jan 27, 2026 | Sale | Brian T. Powl (Chief Commercial Officer) sold 6,414 shares at $8.46 ($54K). Holdings down 3% to 183,275 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 27, 2026 |
| Jan 27, 2026 | Sale | Kathleen Ford (President / COO) sold 1,813 shares at $8.46 ($15K). Holdings down 1% to 153,560 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 27, 2026 |
| Jan 27, 2026 | Sale | Mollie Leoni (Chief Medical Officer) sold 8,180 shares at $8.46 ($69K). Holdings down 3% to 267,274 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 27, 2026 |
| Jan 27, 2026 | Sale | Thomas James Doyle (SVP, Finance & Accounting) sold 7,142 shares at $8.46 ($60K). Holdings down 5% to 145,167 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 27, 2026 |
| Jan 27, 2026 | Sale | Teresa Brophy Bair (Chief Legal Officer) sold 11,208 shares at $8.46 ($95K). Holdings down 5% to 226,931 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 27, 2026 |
| Dec 9, 2025 | Planned (10b5-1) | Faheem Hasnain (Director) sold 10,000 shares at about $10.98 ($110K), marked as a 10b5-1 plan trade. Holdings down 29% to 23,983 shares. | SEC filing Filed Dec 10, 2025 |
| Nov 14, 2025 | Planned (10b5-1) | Teresa Brophy Bair (Chief Legal Officer) sold 8,804 shares at $11.18 ($98K), marked as a 10b5-1 plan trade. Holdings down 4% to 188,139 shares. | SEC filing Filed Nov 14, 2025 |
| Nov 14, 2025 | Sale | Brian T. Powl (Chief Commercial Officer) sold 8,887 shares at $11.18 ($99K). Holdings down 6% to 139,689 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 14, 2025 |
| Nov 14, 2025 | Sale | Mollie Leoni (Chief Medical Officer) sold 15,485 shares at $11.18 ($173K). Holdings down 6% to 225,454 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 14, 2025 |
| Nov 14, 2025 | Sale | Thomas James Doyle (SVP, Finance & Accounting) sold 4,539 shares at $11.18 ($51K). Holdings down 3% to 130,257 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 14, 2025 |
| Nov 14, 2025 | Planned (10b5-1) | Kathleen Ford (President / COO) sold 6,902 shares at $11.18 ($77K), marked as a 10b5-1 plan trade. Holdings down 6% to 105,373 shares. | SEC filing Filed Nov 14, 2025 |
28 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow KURA in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.